Sepracor Will Support Xopenex HFA Launch With Three Sales Forces
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm will use two primary care sales forces and one specialty respiratory sales force to detail the hydrofluoroalkane metered-dose inhaler.
You may also be interested in...
Sepracor Seeks FDA Nod For Long-Acting Beta Agonist Arformoterol
User fee date for the chronic obstructive pulmonary disease agent would fall in October, assuming a standard 10-month review.
CFC-Containing Albuterol Inhalers To Be Removed By 2009
FDA's final rule sets a deadline one year earlier than the latest possible date suggested in the proposed rule. Manufacturers have said that once a phase-out date was set they could build sufficient supply of ozone-friendly albuterol product within 18 months.
Future BIO Global Efforts Include International Relations, Greenwood Says
HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13